Rigel Pharmaceuticals, Inc. (RIGL) financial statements (2021 and earlier)

Company profile

Business Address 1180 VETERANS BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments98107112128129116135
Cash and cash equivalents23394475766165
Short-term investments76686853525470
Receivables101276432
Inventory, net of allowances, customer advances and progress billings1111110
Inventory1111110
Deferred rent asset     00
Advances on inventory purchases3      
Other undisclosed current assets6645322
Total current assets:119126125139137121139
Noncurrent Assets
Property, plant and equipment2222111
Other noncurrent assets1111111
Other undisclosed noncurrent assets26282931   
Total noncurrent assets:29303233222
TOTAL ASSETS:148156156173139123141
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20171512201412
Accounts payable4341633
Accrued liabilities7757443
Employee-related liabilities97641075
Contract with customer, liability2521   
Other undisclosed current liabilities13131214865
Total current liabilities:58312826282017
Noncurrent Liabilities
Long-term debt and lease obligation1010     
Long-term debt, excluding current maturities1010     
Liabilities, other than long-term debt72526 0 0
Deferred revenue and credits00
Contract with customer, liability12526   
Other liabilities5     0
Total noncurrent liabilities:163526 0 0
Total liabilities:75665526282018
Stockholders' equity
Stockholders' equity attributable to parent54697895110103124
Common stock0000000
Additional paid in capital1,3301,3281,3261,3221,3191,3161,312
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(1,276)(1,259)(1,248)(1,227)(1,209)(1,213)(1,189)
Total stockholders' equity:54697895110103124
Other undisclosed liabilities and equity192123511  
TOTAL LIABILITIES AND EQUITY:148156156173139123141

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues152110133852
Revenue, net52
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)(0)(0)(0)(0)(0)
Gross profit:152110133852
Operating expenses(33)(33)(31)(31)(35)(29)(28)
Operating income (loss):(17)(12)(21)(18)3(24)(26)
Nonoperating income
(Investment Income, Nonoperating)
1111111
Interest and debt expense(0)(0)     
Income (loss) before gain (loss) on sale of properties:(17)(11)(21)(17)3(24)(26)
Other undisclosed net loss(0)  (0)(0)  
Net income (loss) available to common stockholders, diluted:(17)(11)(21)(18)3(24)(26)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(17)(11)(21)(18)3(24)(26)
Comprehensive income (loss):(17)(11)(21)(18)3(24)(26)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)00000
Comprehensive income (loss), net of tax, attributable to parent:(17)(11)(21)(18)3(24)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: